FDA grants an ex­pand­ed Ay­vak­it la­bel to Blue­print Med­i­cines

The FDA on Mon­day ap­proved Blue­print Med­i­cines’ Ay­vak­it for a much broad­er, though still rare pop­u­la­tion of pa­tients with in­do­lent sys­temic mas­to­cy­to­sis, a dis­ease in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER